CytoSorbents Corp CTSO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CTSO is a good fit for your portfolio.
News
-
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
-
CytoSorbents Secures $20 Million Credit Facility
-
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
-
CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union
-
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
-
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
-
CytoSorbents Reports First Quarter 2024 Results
-
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
Trading Information
- Previous Close Price
- $1.03
- Day Range
- $0.98–1.04
- 52-Week Range
- $0.70–3.80
- Bid/Ask
- $1.01 / $1.05
- Market Cap
- $55.94 Mil
- Volume/Avg
- 25,273 / 108,306
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 186
- Website
- https://www.cytosorbents.com
Comparables
Valuation
Metric
|
CTSO
|
EMBC
|
SIBN
|
---|---|---|---|
Price/Earnings (Normalized) | — | 4.54 | — |
Price/Book Value | 2.98 | — | 4.01 |
Price/Sales | 1.53 | 0.80 | 4.48 |
Price/Cash Flow | — | 8.15 | — |
Price/Earnings
CTSO
EMBC
SIBN
Financial Strength
Metric
|
CTSO
|
EMBC
|
SIBN
|
---|---|---|---|
Quick Ratio | 1.15 | 1.50 | 8.63 |
Current Ratio | 1.49 | 2.29 | 9.76 |
Interest Coverage | −278.69 | 1.45 | −13.62 |
Quick Ratio
CTSO
EMBC
SIBN
Profitability
Metric
|
CTSO
|
EMBC
|
SIBN
|
---|---|---|---|
Return on Assets (Normalized) | −45.27% | 12.15% | −7.83% |
Return on Equity (Normalized) | −102.59% | — | −10.72% |
Return on Invested Capital (Normalized) | −56.96% | 28.15% | −10.92% |
Return on Assets
CTSO
EMBC
SIBN
Medical Devices Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Abbott Laboratories
ABT
| Tnvpdytj | Qmrplsb | $183.1 Bil | |||
Stryker Corp
SYK
| Bylyhhctfp | Zqf | $126.3 Bil | |||
Boston Scientific Corp
BSX
| Dhphbfwy | Zwhpr | $110.1 Bil | |||
Medtronic PLC
MDT
| Jnczztlnp | Smwwqr | $100.9 Bil | |||
Edwards Lifesciences Corp
EW
| Wvzswlgys | Ttthrm | $37.6 Bil | |||
DexCom Inc
DXCM
| Ksbsjphzpx | Zdtk | $25.6 Bil | |||
Koninklijke Philips NV ADR
PHG
| Jxqfxjfsx | Xpvmgp | $24.1 Bil | |||
Steris PLC
STE
| Fhlhfcymt | Pcsrqp | $23.0 Bil | |||
Zimmer Biomet Holdings Inc
ZBH
| Nzbtjjcyh | Msxnp | $22.9 Bil | |||
Align Technology Inc
ALGN
| Rbjvsrv | Zbpvsb | $16.6 Bil |